Platinum-based drugs and hydrogel: a promising anti-tumor combination

Drug Deliv. 2023 Dec;30(1):2287966. doi: 10.1080/10717544.2023.2287966. Epub 2023 Dec 11.

Abstract

Platinum-based drugs are widely used as first-line anti-tumor chemotherapy agents. However, they also have nonnegligible side effects due to the free drugs in circulation. Therefore, it is necessary to develop efficient and safe delivery systems for better tumor cell targeting. Hydrogel is a promising anti-tumor drug carrier that can form a platinum/hydrogel combination system for drug release, which has shown better anti-tumor effects in some studies. However, there is a lack of systematic summary in this field. This review aims to provide a comprehensive overview of the platinum/hydrogel combination system with the following sections: firstly, an introduction of platinum-based drugs; secondly, an analysis of the platinum/hydrogel combination system; and thirdly, a discussion of the advantages of the hydrogel-based delivery system. We hope this review can offer some insights for the development of the platinum/hydrogel combination system for better cancer therapy.

Keywords: Platinum-based drugs; anti-cancer; combination system; drug delivery; hydrogel.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents*
  • Drug Delivery Systems
  • Humans
  • Hydrogels
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Platinum / therapeutic use

Substances

  • Hydrogels
  • Antineoplastic Agents
  • Platinum

Grants and funding

This work was supported by the National Natural Science Foundation of China (NSFC) #1 under Grant number 32200577; Applied Basic Research Project of Sichuan Province #2 under Grant number 2023NSFSC1502, 2021YJ0021; 2022NSFSC0289; 2022ZYD0053 and Research Funding for Talents Developing, West China Hospital of Stomatology Sichuan University #3 under Grant number RCDWJS2020-04, QDJF2022-1.